The TMED2 in ovarian mucinous adenocarcinoma, ovarian serous adenocarcinoma and ovarian endometrioid adenocarcinoma was moderate expression(Figure 1B(I-III)). This evidence concerns the gene TMED2 and ovarian endometrioid adenocarcinoma.